Hydroxychloroquine and QTc: beyond COVID-19

Submitted: 28 April 2020
Accepted: 31 August 2020
Published: 1 October 2020
Abstract Views: 749
PDF: 414
HTML: 5
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Hydroxychloroquine is an antimalarial drug also known for its anti-inflammatory and antiviral effects, which have raised the interest of many researchers for its potential use in COVID-19 patients. It is known that this drug, being able to influence the cardiac repolarization phase with QTc interval prolongation, can be potentially harmful, chiefly in elderly subjects with frailty syndrome, several comorbidities and polypharmacotherapy. Therefore, although electrocardiogram monitoring of QTc prolongation is the focal point for reducing the arrhythmic risk of these patients, in order to identify the most exposed patients, the traditional Comprehensive Geriatric Assessment should be combined with a multiparametric risk score for QTc prolongation.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Castagna, A., Vetta, F., Attisani, G., Costa, R., Ruberto, C., Vespertini, V., Cosco, L., & Ruotolo, G. (2020). Hydroxychloroquine and QTc: beyond COVID-19. Geriatric Care, 6(3). https://doi.org/10.4081/gc.2020.9064

Similar Articles

You may also start an advanced similarity search for this article.